9 / 18
Page 63
conferenceseries
.com
Volume 2, Issue 4 (Suppl)
Breast Can Curr Res, an open access journal
Breast Pathology 2017
August 23-24, 2017
August 23-24, 2017 Toronto, Canada
4
th
World Congress on
Breast Pathology and Cancer Diagnosis
MicroRNAs expression profiles as novel biomarkers for the diagnosis, prognosis of breast cancer
Fouad M Badr
Suez Canal University, Egypt
M
icroRNAs (miRNAs) are short, non-coding RNA molecules of 19-25 nt, involved in a wide array of physiological and
pathological processes by modulating the expression of their cognate target genes through cleaving mRNA molecules
or inhibiting their translation. In cancer, microRNAs can act as oncogenes or tumor suppressor genes. Oncogenic miRNAs
may be amplified, resulting in increased expression of the oncomir. Tumor-suppressive miRNAs could reside in chromosome
fragile sites characterized by deletions or mutations, leading to reduced levels of these miRNAs. Some miRNAs are emerging as
a novel class of potential biomarkers for early breast cancer (BC) diagnosis, prognosis, and prediction of therapeutic outcomes.
MiRNAs are of interest as easily accessible, affordable, non-invasive tools for the management of patients with BC. MicroRNA
expression signature appears to provide a better characterization of cancer subtypes than gene expression profiling and may
represent a new classification system for breast cancer. Abnormal microRNA expression patterns are closely related to specific
tumor stages, lymph node, steps of the metastasis cascade, poor survival, disease outcomes and responses to specific therapies in
many types of cancer. MicroRNA profiling has been assessed to differentiate patients with BC as responding or not responding
to therapies. MicroRNA deregulation in the development of BC in several tissues and lineages, have correlated miRNA profiles
with mRNA subtypes. In this review, the potential value of these microRNAs as diagnostic and prognostic markers, and the
possible development of microRNA-based therapies will be assessed.
fmbadr@gmail.com